Companies Dominating the Myxedema Coma Landscape
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Pfizer Inc.
- GSK plc.
- Sanofi Global
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Lannett Company, Inc.
- Zydus Lifesciences
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of myxedema coma is assessed at USD 2.35 billion.
The myxedema coma market size was valued at USD 2.19 billion in 2024 and is expected to reach USD 3.93 billion by 2037, registering around 4.6% CAGR during the forecast period i.e., between 2025-2037. Higher prevalence of type 1 diabetes and the growing geriatric population will boost the market growth.
North America industry is set to account for largest revenue share of 38% by 2037, impelled by growing prevalence of obesity in the region.
The major players in the market are AbbV, ie Inc., Merck & Co., Inc., Pfizer Inc., GSK plc., Sanofi Global, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Lannett Company, Inc., Zydus Lifesciences
